Ketamine has been on the World Health Organization’s List of Essential Medicines for decades — used in operating rooms, battlefield surgeries, and pediatric care around the world long before it became known as a treatment for depression. The recreational associations that attach to the name are real but historically recent, and they have created a misconception that the drug itself is new, experimental, or inherently dangerous. At Revitalize Ketamine Clinic in Flagstaff, we find that patients who understand ketamine’s actual medical history arrive at their first consultation with far more grounded expectations — and far less unnecessary anxiety about the treatment itself.
The Origins: A Surgical Anesthetic With a Remarkable Safety Record
Ketamine was developed in the early 1960s and entered clinical use as a surgical anesthetic. Its appeal in that context was immediate and specific: unlike other anesthetics available at the time, ketamine does not suppress the body’s cardiovascular or respiratory systems (Johns Hopkins University). That single property made it uniquely valuable in settings where monitoring was limited — field medicine, pediatric surgery, emergency care — because it sedated patients without the risk of breathing or cardiac suppression that made other agents dangerous in the same contexts.
The US military used ketamine as a battlefield anesthetic beginning in the Vietnam War, and it has remained a staple of trauma medicine and pediatric surgery globally ever since. Its use in veterinary medicine contributed to its later cultural association with recreational drug scenes, but that context tells you nothing useful about how it functions at the precise, controlled doses used in a clinical infusion setting. The dose, the route of administration, the rate of delivery, and the monitoring environment are all completely different. A surgical anesthetic administered under clinical supervision and a substance used recreationally in uncontrolled settings are not meaningfully the same thing.
How Researchers Discovered the Antidepressant Effect
The pivot from anesthetic to antidepressant was not planned. Researchers studying ketamine’s effects on the brain noticed that patients receiving it for surgical purposes sometimes reported rapid, dramatic improvements in mood — changes that appeared faster and in some cases more profound than anything produced by conventional antidepressants. That observation prompted systematic investigation.
Researchers at Yale published the first major study on ketamine’s antidepressant properties in 2000, and the subsequent two decades produced controlled, double-blind, peer-reviewed studies at institutions including the NIH, the VA, Harvard, Johns Hopkins, Mount Sinai Medical School, and Oxford University. What that body of research established is that ketamine’s antidepressant mechanism works through a completely different pathway than the SSRIs and SNRIs that had dominated psychiatric treatment for decades.
The key is the glutamate system — the brain’s primary excitatory neurotransmitter network (National Institutes of Health). Ketamine works by blocking NMDA receptors, proteins that regulate glutamate transmission. This NMDA receptor blockade triggers rapid changes in synaptic plasticity — the brain’s ability to form and strengthen connections — producing antidepressant effects in hours rather than the weeks required by serotonin-targeted medications. That speed, and the fact that ketamine reaches a neurobiological pathway that SSRIs do not, is why it became relevant for treatment-resistant depression: a condition defined by inadequate response to two or more conventional antidepressant trials.
FDA Approval, Scheduling, and What “Off-Label” Means
Ketamine’s FDA-approved indication is as an anesthetic, and that has been the case since its approval in 1970. Its use for depression, PTSD, anxiety, chronic pain, and other psychiatric and pain conditions is considered off-label — meaning it is prescribed outside the FDA’s approved anesthetic indication based on clinical evidence. Off-label prescribing is legal, common, and routine in American medicine. An estimated one in four prescription medications in the United States are prescribed off-label.
The exception is SPRAVATO® — esketamine nasal spray, a derivative of ketamine — which received FDA approval specifically for treatment-resistant depression in adults. SPRAVATO® treatment is the only form of ketamine-based treatment with an FDA approval for a psychiatric indication, and it is available at Revitalize as a distinct treatment option from IV ketamine. Both work through related glutamate-based mechanisms, but they differ in route of administration, dosing protocol, and the clinical populations for which they are indicated.
In the United States, ketamine is classified as a DEA Schedule III controlled substance — the same schedule as anabolic steroids and certain combination opioid products. Schedule III indicates a recognized medical use with moderate potential for dependence — a categorization that reflects the clinical and regulatory reality of the drug, not a judgment about its therapeutic value when administered properly.
What the Safety Profile Actually Looks Like at Therapeutic Doses
At the low doses used for antidepressant infusions, ketamine has a well-characterized safety profile. Research from the National Institutes of Health confirms that side effects from a single antidepressant dose of intravenous ketamine are mild and brief — most commonly mild nausea, temporary drowsiness, and a transient dissociative state during the infusion that resolves before patients leave the clinic (National Institutes of Health). The most consistent physiological effect is a temporary increase in heart rate and blood pressure, which is why vital sign monitoring throughout every infusion is not optional — it is a clinical requirement.
At Revitalize, every infusion is monitored by trained clinical staff. Our team reviews each patient’s cardiovascular history during intake specifically because this is where the primary medical consideration lies. The dissociative experience during the infusion — which patients variously describe as floating, dreaming, or a gentle loosening of ordinary thought — is transient and typically well-tolerated. It is also, notably, part of why set and setting matter. The clinical environment, the preparation, and the follow-up support all shape whether that experience is useful or disorienting.
From History to Practice: Why This Background Matters for Patients
Understanding ketamine’s medical lineage matters for one practical reason: it separates the legitimate clinical question — is this treatment appropriate for me? — from the cultural noise that surrounds the name. Ketamine is not a new, untested substance. It has been administered millions of times across six decades of surgical and anesthetic medicine. The antidepressant application is younger, but it is built on a foundation of serious institutional research — not speculation.
At Revitalize, Casey Dubravcic has been following ketamine’s trajectory as a treatment modality since approximately 2008, years before it became widely discussed in mainstream mental health contexts. That depth of familiarity means our clinical approach is grounded in the wellness model — understanding where the evidence is strong, where it is still developing, and what that means for individual patients. We discuss this honestly during every consultation, including what is well-established and what remains under investigation.
Frequently Asked Questions
Is ketamine the same as the drug used recreationally? It is the same compound, but administered in a completely different context. Recreational ketamine is typically used at much higher doses, in uncontrolled settings, without vital sign monitoring or clinical supervision. The therapeutic doses used in IV infusions are lower, precisely calibrated, and administered with active monitoring throughout. The drug’s effects at those doses are distinct from high-dose recreational use — the dissociative state is mild and transient, not the deep sedation associated with misuse. The analogy would be the difference between a glass of wine and a dangerous blood alcohol level: same substance, fundamentally different clinical reality.
How long has ketamine been used for depression specifically? The first major peer-reviewed study on ketamine’s antidepressant properties was published by Yale researchers in 2000. Clinical practice has built on roughly two and a half decades of research since then, with studies at major institutions including the NIH, Harvard, Johns Hopkins, and others. The research base is not new, though public awareness of it has grown considerably in recent years.
What is the difference between IV ketamine and SPRAVATO®? IV ketamine is administered intravenously in a clinical setting and is used off-label for depression, anxiety, PTSD, and chronic pain. SPRAVATO® is an FDA-approved esketamine nasal spray specifically indicated for treatment-resistant depression. Patients self-administer SPRAVATO® under clinical supervision and remain monitored for two hours after each session. SPRAVATO® is covered by major insurers including Tricare, Blue Cross Blue Shield, Cigna, Evernorth, and Aetna when patients meet clinical criteria. Both are available at Revitalize. Discuss with your provider which option is appropriate for your situation.
Is ketamine addictive? Ketamine has a recognized potential for dependence at high doses with repeated recreational use — which is why it carries a Schedule III classification. At the low doses and controlled frequencies used in therapeutic infusions, dependence is not a documented clinical outcome in the research literature. Patients with a history of substance use disorder are screened carefully during our intake process, as this is a relevant factor in determining candidacy for treatment.
Does a family history of psychosis affect ketamine candidacy? Personal or family history of psychotic disorders is one of the factors reviewed during our clinical screening. Certain psychiatric histories affect candidacy for ketamine treatment, and our intake process exists specifically to surface those factors before any treatment begins. If you have questions about whether your history makes you a suitable candidate, the right place to start is a consultation — we will give you an honest answer.
Key Takeaways
- Ketamine has been an FDA-approved anesthetic and WHO essential medicine for over six decades, with a well-established safety record across surgical and emergency medicine long before its antidepressant properties were documented.
- Its antidepressant mechanism works through the glutamate system via NMDA receptor blockade — a pathway entirely distinct from SSRIs and SNRIs — which explains why it may help patients who have not responded to conventional medications.
- IV ketamine for depression is prescribed off-label, which is legal and routine in medical practice; SPRAVATO® is the FDA-approved esketamine nasal spray specifically indicated for treatment-resistant depression.
- At therapeutic infusion doses, ketamine’s side effect profile is mild and brief; the primary physiological consideration — temporary heart rate and blood pressure elevation — is managed through continuous vital sign monitoring during every session.
- Results vary by individual; a thorough intake evaluation that reviews your medical history, psychiatric history, and medication background is required before treatment begins at Revitalize.
Ketamine’s history is longer and more substantive than most patients realize when they first start researching it. If you want to understand whether IV ketamine or SPRAVATO® is appropriate for your situation, we are ready to have that conversation without the noise. Call Revitalize Ketamine Clinic at 928-589-0567 or request a consultation online. We serve patients across Flagstaff, Sedona, and Prescott Valley.
References
History of Ketamine. Johns Hopkins University. https://publichealth.jhu.edu/2024/what-to-know-about-ketamine
NMDA Receptor / Glutamate System. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC5148235/
Side Effects Mild and Brief: Single Antidepressant Dose of Intravenous Ketamine. National Institutes of Health. https://www.nih.gov/news-events/news-releases/side-effects-mild-brief-single-antidepressant-dose-intravenous-ketamine
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy and SPRAVATO® should only be pursued under the supervision of a licensed provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.